ProQR Therapeutics (PRQR) Tax Provisions (2017 - 2025)
ProQR Therapeutics (PRQR) posted Tax Provisions of $43069.6 for Q4 2025, up 311.38% sequentially from -$20375.3 in Q2 2025, and up 110.23% YoY from $20486.9 in Q4 2024.
ProQR Therapeutics (PRQR) Tax Provisions (2017 - 2025) Analysis & Trends
ProQR Therapeutics has reported Tax Provisions for 9 years, with the latest figure at $43069.6 in Q4 2025.
- Quarterly Tax Provisions rose 110.23% year-over-year to $43069.6 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$398332.3 (down 90.67% YoY) and the FY2025 annual result came in at $22116.8, up 110.51% from the prior year.
- Tax Provisions climbed to $43069.6 in Q4 2025 per PRQR's latest filing, from -$20375.3 in the prior quarter.
- Over five years, Tax Provisions peaked at $215377.5 in Q2 2024 and troughed at -$421026.6 in Q4 2024.
- A 5-year average of -$13832.8 and a median of -$14409.5 in 2025 frame the typical range for Tax Provisions.
- The sharpest annual moves came in 2022 and 2024: Tax Provisions jumped 878.34% in 2022, then sank 7926.21% in 2024.
- Over 5 years, Tax Provisions stood at -$25167.4 in 2021, then surged by 878.34% to $195887.5 in 2022, then sank by 97.25% to $5379.7 in 2023, then tumbled by 7926.21% to -$421026.6 in 2024, then surged by 110.23% to $43069.6 in 2025.
- According to Business Quant data, Tax Provisions over the past three periods registered $43069.6, -$20375.3, and -$421026.6 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 43,069.61 |
| Jun 30, 2025 | -20,375.27 |
| Dec 31, 2024 | -421,026.59 |
| Jun 30, 2024 | 215,377.52 |
| Mar 31, 2024 | -3,259.09 |
| Dec 31, 2023 | 5,379.70 |
| Sep 30, 2023 | -44,632.21 |
| Jun 30, 2023 | 45,734.82 |
| Dec 31, 2022 | 195,887.49 |
| Sep 30, 2022 | -69,570.93 |
| Jun 30, 2022 | -21,341.13 |
| Mar 31, 2022 | -7,856.36 |
| Dec 31, 2021 | -25,167.36 |
| Sep 30, 2021 | -41,275.06 |
| Jun 30, 2021 | -63,826.39 |
| Mar 31, 2021 | -8,443.65 |
| Dec 31, 2020 | -45,307.01 |
| Sep 30, 2020 | -87,605.79 |
| Jun 30, 2020 | -12,116.06 |
| Dec 31, 2019 | -75,268.36 |